Tavin is an antiretroviral medication that treats HIV-1 in adults when taken with other anti-HIV drugs. One pill contains 300mg of tenofovir disoproxil fumarate. It is highly effective, yet Tavin must be part of a regiment of multiple antiretrovirals to stop HIV-1 from progressing to AIDS.
Dosing and Administration
One 300mg pill should be consumed orally with or without food once a day. Because Tavin has been documented to affect kidney functions, patients with a creatinine clearance of 30-49 mL/min should only take one dose every 48 hours. Those with a creatinine clearance of 10-29 mL/min may take one 300 mg pill two times a week, while patients undergoing hemodialysis should be restricted to one pill every seven days or 12 hours after dialysis.
Anyone hypersensitive to tenofovir disoproxil fumarate should not take Tavin.
Several mild side effects have been commonly reported by patients taking Tavin including:
Some less common but severe side effects that have been documented are:
- renal impairment or failure
- interstitial nephritis
- fanconi syndrome
- hepatomegaly with steatosis
- lactic acidosis
- tubular necrosis
- nephrogenic diabetes insipidus
Other adverse effects have been reported by patients taking Tavin. Let your doctor know if you experience any changes in your physical or mental health after beginning to take Tavin.
Precautions and Warnings
Some patients show symptoms of immune reconstitution syndrome when first starting Tavin. Patients with hepatitis B can experience acute exacerbation of hepatitis symptoms after they discontinue tenofovir disoproxil fumarate. The safety and effectiveness of administering Tavin to patients co-infected with hepatitis B and HIV has yet be established, and hepatitis patients should be closely monitored for several months after they stop using Tavin. Patients taking Tavin have also reported loss in bone mineral density and osteomalacia. Taking nephrotoxic drugs with Tavin might increase the risk of renal implications.
Tavin should not be taken with didanosine, lamivudine or abacavir because these drugs can sometimes render Tavin ineffective. Co-administering atazanavir or lopinavir/ritonavir with Tavin can worsen the side effects of Tavin. Tavin should be discontinued if this occurs. Tavin can decrease the AUC and Cmin of atazanavir; atazanavir without ritonavir should not be co-administered with Tavin.
Pregnancy and Breastfeeding
Laboratory testing has revealed no increased risk of birth defects when administering Tavin to pregnant animals, and no reports of birth defects related to taking Tavin have been documented in humans; however, new mothers are discouraged from breastfeeding due to the possible risk of transmitting HIV to their infant.
Patients who take more than their prescribed dose of Tavin should be monitored for toxicity. The patient may have to undergo haemodialysis to purge the excess medication from their body.
Reviews are only written by verified customers who have purchased this product.